No Effect of Cloricromen on Some Coagulation Parameters in Patients with Ischaemic Cerebrovascular Disease

Abstract

Cloricromen is a new drug that inhibits platelet aggregation in man and in experimental thrombosis. Twenty patients with a history of atherothrombotic stroke received cloricromen (100 mg, twice daily) for 30 days in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system. A statistically significant decrease in the prothrombin time (P < 0.01) was found only after 30 days of therapy. This decrease was transient and disappeared 15 days after the end of treatment. No statistically significant changes in plasma fibrinogen levels, antithrombin III, partial thromboplastin time, or platelet count were observed compared with baseline values. No side-effects were reported. This study did not reveal an effect of cloricromen on coagulative variables in patients with cerebrovascular occlusive disease.

Keywords

Cloricromen Antiplatelet Drugs Ischaemic Stroke Prothrombin Time Plasma Fibrinogen Level Antithrombin III Haemostatic System

Get full access to this article

View all access options for this article.

References

Feinberg

Bruck

Ring

Hemostatic markers in acute stroke. Stroke 1989; 20: 592–597.

Gawel

Activation of coagulation and fibrinolytic systems after stroke. In: Cerebrovascular Diseases ( Plum

Pulsinelli

eds). New York: Raven Press, 1985; pp 225–228.

Swedish Cooperative Study: High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987; 18: 325–334.

Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J 1988; 296: 320–331.

Walsh

Schmaicr

Platelet-coagulation protein interactions. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice ( Colman

ed). Philadelphia: JB Lippincott, 1987; pp 689–709.

The SALT Collaborative Group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–1349.

Galli

Agradi

Petroni

Effect of AD6 on aggregation, arachidonic acid metabolism and thromboxane B₂ formation in human platelets. Pharmacol Res Commun 1980; 12: 329–337.

Prosdocimi

Finesso

Tessari

Inhibition by AD6 of platelet aggregation in dog stenosed coronary artery. Thromb Res 1985; 39: 399–409.

Tohgi

Kawashima

Tamura

Coagulation—fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke 1990; 21: 1663–1667.

10.

Wilhelmsen

Svardsudd

Korsan-Bensten

Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–505.

11.

Lowe

GDO

Blood rheology in arterial disease. Clin Sr 1986; 71: 137–146.

12.

Watanabe

Tanaka

Influence of fibrin, fibrinogen and fibrinogen products on cultured endothelial cells. Atherosclerosis 1983; 48: 57–61.

13.

Meade

Vickers

Thompson

The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527–534.

14.

Editorial: Coagulation abnormalities and cerebral infarction. J Neurol Neurosurg Psychiatry 1993; 56: 433–439.

15.

Dejana

De Castellarnau

Baiconi

AD6, a coronary dilating agent, stimulates PGI₂ production in rat aorta ex vivo and in human endothelial cells in culture. Pharmacol Res Commun 1982; 14: 719–724.

16.

Prencipe

Lazzaro

Orlandi

Drug-induced modifications of some coagulation parameters in 50 TIA patients. In: Pharmacology of Cerebral Ischemia ( Krieglstein

ed). Amsterdam: Elsevier Science Publishers B.V., 1986; pp 417–421.